Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod IncfiledCriticalPfizer Prod Inc
Priority to UY26164ApriorityCriticalpatent/UY26164A1/en
Publication of UY26164A1publicationCriticalpatent/UY26164A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Profármacos mutuos de amlodipino y atorvastatina y a las composiciones farmacéuticas de los mismos. Procedimientos para tratar la angina de pecho, la aterosclerosis y la hipertensión y la hiperlipidemia en un mamífero mediante el uso de estos profármacos y composiciones. Procedimientos para tratar el riesgo cardíaco en un mamífero, incluyendo humanos, que presenta síntomas de riesgo cardíaco mediante la administración de estos profármacos y composiciones.Mutual prodrugs of amlodipine and atorvastatin and to the pharmaceutical compositions thereof. Procedures for treating angina pectoris, atherosclerosis, and hypertension and hyperlipidemia in a mammal through the use of these prodrugs and compositions. Procedures for treating cardiac risk in a mammal, including humans, exhibiting cardiac risk symptoms by administration of these prodrugs and compositions.
UY26164A2000-05-252000-05-25
MUTUAL PROPHARMACS OF AMLODIPINE AND ATORVASTATIN
UY26164A1
(en)
A compound n- (4-chloro-3- (pyridin-2-yl) phenyl) -4- (2-hydroxy-2-methylpropylsulfonyl) -2-methylbenzamide, inhibitor of the hedgehog signaling pathway; pharmaceutical composition comprising said compound; and its use to treat cancer.